The Consell de Govern has authorised an investment of €2,219,609.60 to the Blood and Tissue Bank Foundation of the Balearic Islands (FBSTIB) for the procurement of therapeutic plasma-derived medicines, obtained through the industrial fractionation of human plasma collected from local blood donations.

These plasma-derived products are vital biological medicines used in the treatment of rare and hereditary diseases, often with no therapeutic alternatives. They also play a crucial role in hospital care for burn victims, major surgeries, autoimmune diseases, hepatitis, RH incompatibility, trauma, and bleeding disorders. Key products include albumin, immunoglobulins, and coagulation factors, essential for restoring blood volume and supporting patients in critical conditions.

TDB keeps you informed. Follow us on: Facebook, Twitter and Instagram

Investment of €2.2 million approved to ensure the supply of plasma-derived medicines in the Balearic Islands

The contract will be multi-year and pre-financed, covering 2026 to 2028, with the option of extending it for up to three additional years and allowing for adjustments of up to 20 % of the original budget. The investment will be allocated progressively: €554,902.40 in 2026, €1,109,804.80 in 2027, and €554,902.40 in 2028.

This initiative strengthens the commitment to transfusion safety and self-sufficiency in plasma-derived medicines, ensuring the continuity of an essential public health service that supports the entire population of the Balearic Islands.